Identity
Pemvidutide is an investigational GLP-1/glucagon dual-receptor agonist.
Selected study only; not a complete clinical review.
Peptide library
Pemvidutide
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The phase IIb study met the MASH-resolution endpoint but not the fibrosis-improvement endpoint. Histological changes at 24 weeks do not prove prevention of cirrhosis, transplantation or death.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
212 adults with biopsy-confirmed MASH and F2/F3 fibrosis; phase 2b.
What the sources found
At 24 weeks, MASH resolution met its primary endpoint; fibrosis improvement did not meet the other primary endpoint.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Pemvidutide is an investigational GLP-1/glucagon dual-receptor agonist.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Adverse events were more frequent with active treatment, mostly mild or moderate.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
At 24 weeks, MASH resolution met its primary endpoint; fibrosis improvement did not meet the other primary endpoint.
Selected study only; not a complete clinical review.
Adverseeffects
Adverse events were more frequent with active treatment, mostly mild or moderate.
Selected study only; not a complete clinical review.
References
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. 2025.
PMID: 41237796
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.